Listeria monocytogenes is a leading cause of community-acquired acute meningitis [1]. Optimal treatment is still uncertain, and there are no prospective, controlled trials with adequate numbers of patients [2]. We report a case of listerial meningitis that developed during treatment with oral ciprofloxacin. This case calls into question the efficacy of quinolones in the management of severe listerial infection.
Development of Listerial Meningitis during Ciprofloxacin Treatment
Listeria monocytogenes is a leading cause of community-acquired acute meningitis [1] . Optimal treatment is still uncertain, and there are no prospective, controlled trials with adequate numbers of patients [2] . We report a case of listerial meningitis that developed during treatment with oral ciprofloxacin. This case calls into question the efficacy of quinolones in the management of severe listerial infection.
A 62-year-old man was found to be febrile and unresponsive at home after having a severe headache and increasing lethargy. Five days before, while on a Mediterranean cruise, he had developed nausea, headache, and general malaise. While on the ship, the patient and his wife ate soft cheeses and assorted cold cuts of beef, pork, and poultry. The ship's physician treated him with oral ciprofloxacin (500 mg twice a day) for a total of 5 days. During the first 3 days of treatment, his condition transiently improved. However, despite continuing ciprofloxacin therapy, he developed headache and lethargy. He had a history of hairy cell leukemia 11 years before (at which time he underwent splenectomy), and he had a history of asthma treated with prednisone (5 mg/d).
At the time of admission, he developed generalized seizures. Analysis of CSF revealed a white blood cell count of 381/mL (68% segmented neutrophils and 32% lymphocytes), protein level of 573 mg/dL, and glucose level of 171 mg/dL. Gram staining of CSF revealed polymorphonuclear cells but no microorganisms. Computed tomography of the brain (without contrast medium) was unremarkable. Initial therapy was ceftriaxone, vancomycin, acyclovir, ampicillin (2 g intravenously every 4 h), and gentamicin (150 mg intravenously every 12 h). Treatment with ceftriaxone and vancomycin was discontinued on the second hospital day once CSF cultures yielded L. monocytogenes, and acyclovir administration was discontinued on the fifth hospital day, when PCR analysis was negative for herpesviruses.
The patient had severe upper extremity tremor, memory loss, and ataxic gait. With antibiotic therapy, the patient's neurological status slowly improved. He received ampicillin and gentamicin for a total of 42 and 14 days, respectively. After 2 years of follow-up, he has achieved a near-complete recovery.
The patient developed listerial meningitis despite concurrent ciprofloxacin treatment. He was immunocompromised in that he did have a history of hairy cell leukemia and was asplenic. In addition, he was receiving daily treatment with low doses of oral prednisone.
Current guidelines for treatment of CNS infection due to Listeria include ampicillin combined with gentamicin [3, 4] . The duration of treatment should be at least 21 days [3] . The patient received 6 weeks of ampicillin therapy because of recurrent seizure activity.
A MEDLINE search of the literature from 1966 to May 1999 with the key words "Listeria" and "ciprofloxacin" or "quinolone" revealed no previous reports of listerial infection developing during quinolone therapy. Most reports of quinolone activity against L. monocytogenes have involved in vitro testing.
The mode of spread of Listeria is primarily through contaminated food [3] . Among food-related infections, listeriosis has a high case-fatality rate (∼25%) [1] .
Ciprofloxacin has been demonstrated to be bacteriostatic against Listeria [4] in usual concentrations. Of the "older" quinolones, ciprofloxacin is the most effective against L. monocytogenes [5] , although enoxacin [6] , norfloxacin [5] [6] [7] , ofloxacin [5, 6] , pefloxacin [5] , and levofloxacin [7, 8] have been found to inhibit Listeria in vitro.
The newer fluoroquinolones have exhibited promising activities against Listeria in vitro. Sparfloxacin has been shown to be effective [7, 8] , although serum concentrations attained following oral administration are below required therapeutic levels [8] . Trovafloxacin is more potent than sparfloxacin, with an MIC 90 р0.25 mg/mL [7] . Clinafloxacin has been found to have better activity against Listeria than ampicillin and ciprofloxacin [4] , and levels of clinafloxacin needed for in vitro bactericidal activity can be attained in humans with an oral dose of 100 mg [8] .
In vivo studies of the activities of ciprofloxacin and other quinolones against L. monocytogenes are scarce. In mice inoculated with L. monocytogenes, ciprofloxacin (administered intraperitoneally and intravenously in very high doses [up to 2 mg twice a day]) was shown to decrease bacterial counts [9] . Ciprofloxacin was ineffective in the management of listeriosis in an experimental model of mice pretreated with hydrocortisone [10] . The new fluoroquinolone clinafloxacin was able to reduce bacterial counts below detectable limits in both immunocompetent and immunocompromised mice, while ampicillin and ciprofloxacin were only bacteriostatic. Clinafloxacin also had a significant postantibiotic effect against Listeria, unlike ampicillin even at high concentrations [4] .
We describe a patient who developed meningitis due to L. monocytogenes during treatment with ciprofloxacin. This case does not support the use of ciprofloxacin in the management of CNS listeriosis. Despite promising activities of the newer fluoroquinolones against Listeria, further in vitro and in vivo studies are needed to evaluate their efficacy as possible antimicrobial agents in the management of listeriosis. 
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